Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
|Videos|October 3, 2016
How Can Access to Costly Specialty Drugs be Improved?
Author(s)Lauren Santye, Assistant Editor
Kevin James, RPh, MBA, vice president of payer strategy at US Bioservices, discusses challenges for patients in accessing specialty medications.
Advertisement
Kevin James, RPh, MBA, vice president of payer strategy at US Bioservices, discusses challenges for patients in accessing specialty medications.
Advertisement
Related to this article
FDA clears tiratricol for MCT8 deficiency, lowering dangerous T3 and outlining dosing, lab testing, and pharmacy access.
AI-driven coding fuels specialty EHRs and telehealth tools, making ePrescribing faster, tailored, and affordable while shifting focus to workflow and compliance.
The once-daily tablet is the third approved treatment for fibrodysplasia ossificans progressiva (FOP), with CYP3A4 and metformin interaction guidance.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Tirzepatide Linked to More Weight Loss Than Semaglutide 7.2 mg
2
Pharmacist, Advocate, Ally: Delivering Comprehensive Gender-Affirming Care
3
Statin Myths: Why Patients Avoid Cholesterol-Lowering Therapy
4
Semaglutide 2 mg Tied to Lower MACE Risk Than Tirzepatide Switch
5